Definitive Healthcare Corp. (DH)

Q: What's priced into Definitive Healthcare Corp. (DH) stock?

DH is described as cheap versus peers, while the expectations gap is negative, suggesting expectations are already cautious. The priced-in assessment is marked justified, with low fragility, but confidence in the valuation model is medium.

Q: What does the Definitive Healthcare Corp. (DH) outlook hinge on?

The multi-year thesis depends on customer expansion, improved retention, and the AI-powered platform helping restore sustained revenue growth while cost discipline supports profitability. Near term, another guidance cut or further weakening in jobs data would add pressure; continued strong results and higher guidance from sector bellwethers could support the sector backdrop.

NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-23

$1.080.00%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Definitive Healthcare Corp.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

0.0%

+10% or more+5%0%−5%−10% or less

0.19 → 0.19 EPS · FY ending Dec 31, 2027 · 5 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 5 to 5; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q3
Revenue	$54M–$55M	—
EBITDA	$13.5M–$14.5Mnon-GAAP	—
Operating income	$10.5M–$11.5Mnon-GAAP	—
FY 2026 · Q4
Revenue	—	55.6M
EPS	—	0.04
FY 2026 · Annual
Revenue	$220M–$222M	221.23M
EPS	—	0.195
EBITDA	$57M–$59Mnon-GAAP	—
Operating income	$45.5M–$47.5Mnon-GAAP	—
FY 2027 · Annual
Revenue	—	221.07M
EPS	—	0.187

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Adjusted net income positive $23M to $27M in 2026	It targets $23M to $27M adjusted net income.	Intact	adjusted net income remains negative in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Full-year 2026 revenue near $223 million	A primary condition in Definitive Healthcare Corp.'s published investment case. The stated target is >= $220 million.	Intact	revenue falls below $220 million in FY26	Revenue: $55.195M FY2026-Q2; GAAP. Published target: >= $220 million. Target period is not explicitly aligned with this observation. Source published Aug 10, 202655,195,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: c999f38d-9295-4dfa-9cba-bb0e6ca33c56. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Price-to-earnings ratio near 4.3 times	A supporting condition in Definitive Healthcare Corp.'s published investment case. The stated target is <= 5 PE.	Intact	PE ratio rises above 10 without earnings improvement	P/E (TTM): 5.40x As of 2026-10-23; trailing twelve months. The target timing and basis require a separate assessment. Market data as of Oct 23, 20265.4 ratio · calculatedLast status assessment Oct 24, 2026 Measurement source consolidated · TTM valuation Period ending Oct 23, 2026 Source: mart.stock_valuation_daily. Reference: DH:2026-10-23. Source status: canonical calculation. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$0.19

$0.19 → $0.19 · observed estimates

FY2027 revenue$0.22B

$0.22B → $0.22B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$0.19	$222,799,150	7 / 7
2026-07-25	$0.19	$222,799,150	7 / 7
2026-07-26	$0.19	$222,770,578	5 / 6
2026-07-27	$0.19	$222,770,578	5 / 6
2026-07-28	$0.19	$222,799,150	7 / 7
2026-07-29	$0.19	$222,799,150	7 / 7
2026-07-30	$0.19	$222,770,578	5 / 6
2026-07-31	$0.19	$222,770,578	5 / 5
2026-08-01	$0.19	$222,770,578	5 / 5
2026-08-02	$0.19	$222,799,150	7 / 7
2026-08-03	$0.19	$222,799,150	7 / 7
2026-08-04	$0.19	$222,770,578	5 / 5
2026-08-05	$0.19	$222,770,578	5 / 5
2026-08-06	$0.19	$222,770,578	5 / 5
2026-08-07	$0.19	$222,770,578	5 / 5
2026-08-08	$0.19	$222,799,150	7 / 7
2026-08-09	$0.19	$222,799,150	7 / 7
2026-08-10	$0.19	$222,799,150	7 / 7
2026-08-11	$0.19	$222,799,150	7 / 7
2026-08-12	$0.19	$222,770,578	5 / 5
2026-08-13	$0.19	$221,140,930	7 / 7
2026-08-14	$0.19	$222,770,578	5 / 5
2026-08-15	$0.19	$222,770,578	5 / 5
2026-08-16	$0.19	$222,770,578	5 / 5
2026-08-17	$0.19	$222,770,578	5 / 5
2026-08-18	$0.19	$222,770,578	5 / 5
2026-08-19	$0.19	$222,770,578	5 / 5
2026-08-20	$0.19	$221,067,068	5 / 5
2026-08-21	$0.19	$221,067,068	5 / 5
2026-08-22	$0.19	$221,067,068	5 / 5
2026-08-23	$0.19	$221,067,068	5 / 5
2026-08-24	$0.19	$221,067,068	5 / 5
2026-08-25	$0.19	$221,067,068	5 / 5
2026-08-26	$0.19	$221,067,068	5 / 5
2026-08-27	$0.19	$221,067,068	5 / 5
2026-08-28	$0.19	$221,067,068	5 / 5
2026-08-29	$0.19	$221,067,068	5 / 5
2026-08-30	$0.19	$221,067,068	5 / 5
2026-08-31	$0.19	$221,067,068	5 / 5
2026-09-01	$0.19	$221,067,068	5 / 5
2026-09-02	$0.19	$221,067,068	5 / 5
2026-09-03	$0.19	$221,073,639	5 / 5
2026-09-04	$0.19	$221,073,639	5 / 5
2026-09-05	$0.19	$221,073,639	5 / 5
2026-09-06	$0.19	$221,073,639	5 / 5
2026-09-07	$0.19	$221,073,639	5 / 5
2026-09-08	$0.19	$221,073,639	5 / 5
2026-09-09	$0.19	$221,073,639	5 / 5
2026-09-10	$0.19	$221,073,639	5 / 5
2026-09-11	$0.19	$221,073,639	5 / 5
2026-09-12	$0.19	$221,073,639	5 / 5
2026-09-13	$0.19	$221,073,639	5 / 5
2026-09-14	$0.19	$221,073,639	5 / 5
2026-09-15	$0.19	$221,073,639	5 / 5
2026-09-16	$0.19	$221,073,639	5 / 5
2026-09-17	$0.19	$221,073,639	5 / 5
2026-09-18	$0.19	$221,073,639	5 / 5
2026-09-19	$0.19	$221,073,639	5 / 5
2026-09-20	$0.19	$221,073,639	5 / 5
2026-09-21	$0.19	$221,073,639	5 / 5
2026-09-22	$0.19	$221,073,639	5 / 5
2026-09-23	$0.19	$221,073,639	5 / 5
2026-09-24	$0.19	$221,073,639	5 / 5
2026-09-25	$0.19	$221,073,639	5 / 5
2026-09-26	$0.19	$221,073,639	5 / 5
2026-09-27	$0.19	$221,073,639	5 / 5
2026-09-28	$0.19	$221,073,639	5 / 5
2026-09-29	$0.19	$221,073,639	5 / 5
2026-09-30	$0.19	$221,073,639	5 / 5
2026-10-01	$0.19	$221,073,639	5 / 5
2026-10-02	$0.19	$221,073,639	5 / 5
2026-10-03	$0.19	$221,073,639	5 / 5
2026-10-04	$0.19	$221,073,639	5 / 5
2026-10-05	$0.19	$221,073,639	5 / 5
2026-10-06	$0.19	$221,073,639	5 / 5
2026-10-07	$0.19	$221,073,639	5 / 5
2026-10-08	$0.19	$221,073,639	5 / 5
2026-10-09	$0.19	$221,073,639	5 / 5
2026-10-10	$0.19	$221,073,639	5 / 5
2026-10-11	$0.19	$221,073,639	5 / 5
2026-10-12	$0.19	$221,073,639	5 / 5
2026-10-13	$0.19	$221,073,639	5 / 5
2026-10-14	$0.19	$221,073,639	5 / 5
2026-10-15	$0.19	$221,073,639	5 / 5
2026-10-16	$0.19	$221,073,639	5 / 5
2026-10-17	$0.19	$221,073,639	5 / 5
2026-10-18	$0.19	$221,073,639	5 / 5
2026-10-19	$0.19	$221,073,639	5 / 5
2026-10-20	$0.19	$221,073,639	5 / 5
2026-10-21	$0.19	$221,073,639	5 / 5
2026-10-22	$0.19	$221,073,639	5 / 5
2026-10-23	$0.19	$221,073,639	5 / 5
2026-10-24	$0.19	$221,073,639	5 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	3	8	1
2026-06-01	3	7	2
2026-07-01	2	6	2
2026-08-01	1	5	2
2026-09-01	1	5	2
2026-10-01	1	5	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 1 Buy / Strong Buy · 5 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Adjusted net income positive $23M to $27M in 2026Direct metric needs a verified mapping
Full-year 2026 revenue near $223 millionRevenue: $55.195M
Price-to-earnings ratio near 4.3 timesP/E (TTM): 5.40x

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.6%Typical daily move · historical

Downside history

-78.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Definitive Healthcare Corp. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative growth and turnaround story, not yet a proven durable compounder. The multi-year view is on watch: management is focused on customer growth and profitability, but recent financial performance remains weak.

What's priced into Definitive Healthcare Corp.

DH is described as cheap versus peers, while the expectations gap is negative, suggesting expectations are already cautious. The priced-in assessment is marked justified, with low fragility, but confidence in the valuation model is medium.

What the fundamentals likely do

Near term, revenue pressure remains clear: year-over-year revenue declined in both reported 2026 quarters, while GAAP operating losses continued. Management’s 2026 adjusted-profit guidance is positive, and the GAAP net loss narrowed sharply in Q2, but sustained growth and GAAP profitability are not yet established; the recent earnings miss and CEO transition add uncertainty.

What Definitive Healthcare Corp. hinges on

The multi-year thesis depends on customer expansion, improved retention, and the AI-powered platform helping restore sustained revenue growth while cost discipline supports profitability. Near term, another guidance cut or further weakening in jobs data would add pressure; continued strong results and higher guidance from sector bellwethers could support the sector backdrop.

Bottom line

Over the next 1 to 3 years, DH’s case hinges on turning adjusted-profit progress into durable revenue growth and better GAAP results. The low-fragility priced-in reading is a counterpoint, but weak performance and high business risk leave the thesis unsettled. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q3
Revenue	$54M–$55M	—
EBITDA	$13.5M–$14.5Mnon-GAAP	—
Operating income	$10.5M–$11.5Mnon-GAAP	—
FY 2026 · Q4
Revenue	—	55.6M
EPS	—	0.04
FY 2026 · Annual
Revenue	$220M–$222M	221.23M
EPS	—	0.195
EBITDA	$57M–$59Mnon-GAAP	—
Operating income	$45.5M–$47.5Mnon-GAAP	—
FY 2027 · Annual
Revenue	—	221.07M
EPS	—	0.187

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$0.19

$0.19 → $0.19 · observed estimates

FY2027 revenue$0.22B

$0.22B → $0.22B · observed estimates

Exact estimates & source dates

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$0.19	$222,799,150	7 / 7
2026-07-25	$0.19	$222,799,150	7 / 7
2026-07-26	$0.19	$222,770,578	5 / 6
2026-07-27	$0.19	$222,770,578	5 / 6
2026-07-28	$0.19	$222,799,150	7 / 7
2026-07-29	$0.19	$222,799,150	7 / 7
2026-07-30	$0.19	$222,770,578	5 / 6
2026-07-31	$0.19	$222,770,578	5 / 5
2026-08-01	$0.19	$222,770,578	5 / 5
2026-08-02	$0.19	$222,799,150	7 / 7
2026-08-03	$0.19	$222,799,150	7 / 7
2026-08-04	$0.19	$222,770,578	5 / 5
2026-08-05	$0.19	$222,770,578	5 / 5
2026-08-06	$0.19	$222,770,578	5 / 5
2026-08-07	$0.19	$222,770,578	5 / 5
2026-08-08	$0.19	$222,799,150	7 / 7
2026-08-09	$0.19	$222,799,150	7 / 7
2026-08-10	$0.19	$222,799,150	7 / 7
2026-08-11	$0.19	$222,799,150	7 / 7
2026-08-12	$0.19	$222,770,578	5 / 5
2026-08-13	$0.19	$221,140,930	7 / 7
2026-08-14	$0.19	$222,770,578	5 / 5
2026-08-15	$0.19	$222,770,578	5 / 5
2026-08-16	$0.19	$222,770,578	5 / 5
2026-08-17	$0.19	$222,770,578	5 / 5
2026-08-18	$0.19	$222,770,578	5 / 5
2026-08-19	$0.19	$222,770,578	5 / 5
2026-08-20	$0.19	$221,067,068	5 / 5
2026-08-21	$0.19	$221,067,068	5 / 5
2026-08-22	$0.19	$221,067,068	5 / 5
2026-08-23	$0.19	$221,067,068	5 / 5
2026-08-24	$0.19	$221,067,068	5 / 5
2026-08-25	$0.19	$221,067,068	5 / 5
2026-08-26	$0.19	$221,067,068	5 / 5
2026-08-27	$0.19	$221,067,068	5 / 5
2026-08-28	$0.19	$221,067,068	5 / 5
2026-08-29	$0.19	$221,067,068	5 / 5
2026-08-30	$0.19	$221,067,068	5 / 5
2026-08-31	$0.19	$221,067,068	5 / 5
2026-09-01	$0.19	$221,067,068	5 / 5
2026-09-02	$0.19	$221,067,068	5 / 5
2026-09-03	$0.19	$221,073,639	5 / 5
2026-09-04	$0.19	$221,073,639	5 / 5
2026-09-05	$0.19	$221,073,639	5 / 5
2026-09-06	$0.19	$221,073,639	5 / 5
2026-09-07	$0.19	$221,073,639	5 / 5
2026-09-08	$0.19	$221,073,639	5 / 5
2026-09-09	$0.19	$221,073,639	5 / 5
2026-09-10	$0.19	$221,073,639	5 / 5
2026-09-11	$0.19	$221,073,639	5 / 5
2026-09-12	$0.19	$221,073,639	5 / 5
2026-09-13	$0.19	$221,073,639	5 / 5
2026-09-14	$0.19	$221,073,639	5 / 5
2026-09-15	$0.19	$221,073,639	5 / 5
2026-09-16	$0.19	$221,073,639	5 / 5
2026-09-17	$0.19	$221,073,639	5 / 5
2026-09-18	$0.19	$221,073,639	5 / 5
2026-09-19	$0.19	$221,073,639	5 / 5
2026-09-20	$0.19	$221,073,639	5 / 5
2026-09-21	$0.19	$221,073,639	5 / 5
2026-09-22	$0.19	$221,073,639	5 / 5
2026-09-23	$0.19	$221,073,639	5 / 5
2026-09-24	$0.19	$221,073,639	5 / 5
2026-09-25	$0.19	$221,073,639	5 / 5
2026-09-26	$0.19	$221,073,639	5 / 5
2026-09-27	$0.19	$221,073,639	5 / 5
2026-09-28	$0.19	$221,073,639	5 / 5
2026-09-29	$0.19	$221,073,639	5 / 5
2026-09-30	$0.19	$221,073,639	5 / 5
2026-10-01	$0.19	$221,073,639	5 / 5
2026-10-02	$0.19	$221,073,639	5 / 5
2026-10-03	$0.19	$221,073,639	5 / 5
2026-10-04	$0.19	$221,073,639	5 / 5
2026-10-05	$0.19	$221,073,639	5 / 5
2026-10-06	$0.19	$221,073,639	5 / 5
2026-10-07	$0.19	$221,073,639	5 / 5
2026-10-08	$0.19	$221,073,639	5 / 5
2026-10-09	$0.19	$221,073,639	5 / 5
2026-10-10	$0.19	$221,073,639	5 / 5
2026-10-11	$0.19	$221,073,639	5 / 5
2026-10-12	$0.19	$221,073,639	5 / 5
2026-10-13	$0.19	$221,073,639	5 / 5
2026-10-14	$0.19	$221,073,639	5 / 5
2026-10-15	$0.19	$221,073,639	5 / 5
2026-10-16	$0.19	$221,073,639	5 / 5
2026-10-17	$0.19	$221,073,639	5 / 5
2026-10-18	$0.19	$221,073,639	5 / 5
2026-10-19	$0.19	$221,073,639	5 / 5
2026-10-20	$0.19	$221,073,639	5 / 5
2026-10-21	$0.19	$221,073,639	5 / 5
2026-10-22	$0.19	$221,073,639	5 / 5
2026-10-23	$0.19	$221,073,639	5 / 5
2026-10-24	$0.19	$221,073,639	5 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings